Amendments to the Specification:

Please replace the paragraph beginning at page 22, line 14 (as amended in the paper dated February 6, 2004) with the following rewritten paragraph:

The hybridoma cell lines 1LN-8 (~~shown in the table on page 31~~ shown in Table 2), 3BD-8 (~~shown in the table on page 27~~ shown in Table 1), 3BD-26 (~~shown in the table on page 27~~ shown in Table 1), 3BD-27 (~~shown in the table on page 27~~ shown in Table 1), H460-27 (~~shown in the table on page 46~~ shown in Table 5), H460-23 (~~shown in the table on page 46~~ shown in Table 5), 7BD-14 (~~shown in the table on page 36~~ shown in Table 3) and 5LAC20 (~~shown in the table on page 42~~ shown in Table 4) were deposited, in accordance with the Budapest Treaty, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209 on November 21, 2000 under Accession Numbers PTA-2693, PTA-2696, PTA-2695, PTA-2698, PTA-2699, PTA-2700, PTA-2697 and PTA-2694 respectively. The hybridoma cell lines H460-16-2 (~~shown in the table on page 46~~ shown in Table 5), H460-22-1 (~~shown in the table on page 45~~ shown in Table 5) and 7BDI-60 (~~shown in the table on page 36~~ shown in Table 3) were deposited, in accordance with the Budapest Treaty, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209 on September 4, 2002 under Accession Numbers PTA-4621, PTA-4622 and PTA-4623 respectively. In accordance with 37 CFR 1.808, the depositors assure that all restrictions

imposed on the availability to the public of the deposited materials will be irrevocably removed upon the granting of a patent. The depositors additionally assure that the deposited materials will be replaced if viable samples cannot be dispensed by the depository.

Please delete the paragraph beginning at page 48, line 4 as follows:

~~The anti-cancer antibodies of the invention are useful for treating a patient with a cancerous disease when administered in admixture with a pharmaceutically acceptable adjuvant, for example normal saline, a lipid emulsion, albumen, phosphate buffered saline or the like and are administered in an amount effective to mediate treatment of said cancerous disease, for example with a range of about 1 microgram per mil to about 1 gram per mil.~~

Please delete the paragraph beginning at page 48, line 12 as follows:

~~The method for treating a patient suffering from a cancerous disease may further include the use of conjugated anti-cancer antibodies and would this include conjugating patient specific anti-cancer antibodies with a member selected from the group consisting of toxins, enzymes, radioactive compounds, and~~

~~hematogenous cells; and administering these conjugated antibodies to the patient; wherein said anti-cancer antibodies are administered in admixture with a pharmaceutically acceptable adjuvant, for example normal saline, a lipid emulsion, albumen, phosphate buffered saline or the like and are administered in an amount effective to mediate treatment of said cancerous disease, for example with a range of about 1 microgram per mil to about 1 gram per mil. In a particular embodiment, the anti-cancer antibodies useful in either of the above outlined methods may be a humanized antibody.~~